GENFIT's non-alcoholic steatohepatitis (NASH) diagnostic technology NIS4® has been confirmed for its effectiveness in a study published in Nature Medicine. The study, part of the FNIH Biomarkers Consortium's NIMBLE project, evaluated five blood-based panels, including NIS4®. The findings concluded that NIS4® demonstrated significant superiority over common clinical-laboratory tools for diagnosing at-risk NASH. These findings represent an important milestone in NIS4® technology's path to regulatory approval by the U.S Food and Drug Administration.